A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma

NCT07522879 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Adenoid Cystic Carcinoma
Sinonasal Carcinoma

Interventions

DRUG: Becotatug Vedotin

Sponsor

Eye & ENT Hospital of Fudan University